<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/19/insider-buying-arcadia-biosciences-inc-nasdaqrkda-director-acquires-5000-shares-of-stock.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-19T13:49:33+00:00"/>
    <meta property="og:title" content="Insider Buying: Arcadia Biosciences Inc (NASDAQ:RKDA) Director Acquires 5,000 Shares of Stock"/>
    <meta property="og:description" content="Arcadia Biosciences Inc (NASDAQ:RKDA) Director Lilian Shackelford Murray acquired 5,000 shares of Arcadia Biosciences stock in a transaction on Monday, November 18th. The stock was purchased at an average cost of $4.25 per share, for a total transaction of $21,250.00. Following the purchase, the director now owns 8,524 shares in the company, valued at $36,227. […]"/>
  </head>
  <body>
    <article>
      <h1>Insider Buying: Arcadia Biosciences Inc (NASDAQ:RKDA) Director Acquires 5,000 Shares of Stock</h1>
      <address><time datetime="2019-11-19T13:49:33+00:00">19 Nov 2019, 13:49</time> by <a rel="author" href="https://www.thecerbatgem.com/author/doug" target="_blank">Doug Wharley</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/arcadia-biosciences-inc-logo.jpg"/>
      </figure>
      <p>Arcadia Biosciences Inc (NASDAQ:RKDA) Director Lilian Shackelford Murray acquired 5,000 shares of Arcadia Biosciences stock in a transaction on Monday, November 18th. The stock was purchased at an average cost of $4.25 per share, for a total transaction of $21,250.00. Following the purchase, the director now owns 8,524 shares in the company, valued at $36,227. The transaction was disclosed in a legal filing with the SEC, which is available through <a href="https://www.sec.gov/Archives/edgar/data/1469443/000120919119057084/xslF345X03/doc4.xml">the SEC website</a>.</p>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/NASDAQ/RKDA/insider-trades/">RKDA</a> traded up $0.29 during trading hours on Tuesday, hitting $4.55. The company had a trading volume of 21,130 shares, compared to its average volume of 712,696. The company has a market capitalization of $35.97 million, a PE ratio of -0.85 and a beta of -3.00. The company has a current ratio of 5.58, a quick ratio of 5.27 and a debt-to-equity ratio of 0.11. Arcadia Biosciences Inc has a one year low of $1.82 and a one year high of $10.40. The company’s fifty day moving average price is $4.68 and its two-hundred day moving average price is $4.73.</p>
      <p>Arcadia Biosciences (NASDAQ:RKDA) last released its quarterly earnings results on Wednesday, November 6th. The basic materials company reported ($2.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($1.27). The company had revenue of $0.39 million during the quarter, compared to the consensus estimate of $0.31 million. Arcadia Biosciences had a negative return on equity of 198.10% and a negative net margin of 1,938.76%. Analysts forecast that Arcadia Biosciences Inc will post -3.56 earnings per share for the current year.</p>
      <p>RKDA has been the subject of several research reports. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=RKDA">ValuEngine</a> upgraded Arcadia Biosciences from a “strong sell” rating to a “sell” rating in a report on Sunday, November 3rd. HC Wainwright reiterated a “buy” rating on shares of Arcadia Biosciences in a report on Monday, August 12th. Finally, National Securities upped their target price on Arcadia Biosciences from $12.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, August 15th.</p>
      <p>Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC acquired a new stake in Arcadia Biosciences in the 2nd quarter valued at $32,000. Cambridge Investment Research Advisors Inc. purchased a new position in Arcadia Biosciences in the 2nd quarter valued at about $34,000. Vanguard Group Inc. boosted its position in Arcadia Biosciences by 47.1% in the 2nd quarter. Vanguard Group Inc. now owns 117,059 shares of the basic materials company’s stock valued at $359,000 after buying an additional 37,472 shares during the last quarter. Morgan Stanley boosted its position in Arcadia Biosciences by 162,800.0% in the 2nd quarter. Morgan Stanley now owns 81,450 shares of the basic materials company’s stock valued at $250,000 after buying an additional 81,400 shares during the last quarter. Finally, CVI Holdings LLC purchased a new position in Arcadia Biosciences in the 2nd quarter valued at about $414,000. 6.11% of the stock is owned by hedge funds and other institutional investors.</p>
      <p>
        <b>About Arcadia Biosciences</b>
      </p>
      <p>Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.</p>
      <p>Recommended Story: <a href="https://www.marketbeat.com/financial-terms/understanding-options-trading/">Options Trading</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=RKDA"/>
      </figure>
    </article>
  </body>
</html>